.After revealing a phase 3 launch based on good midstage results, iTeos and GSK are eventually shari...
.The FDA must be more open and collective to release a rise in approvals of unusual health condition...
.It's an extraordinarily occupied Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Ther...
.Atea Pharmaceuticals' antiviral has actually fallen short one more COVID-19 trial, yet the biotech ...
.Neurocrine Biosciences' schizophrenia program pivot has fallen short. The biotech was unable to rep...
.Sanofi has actually created a late entry to the radioligand celebration, paying for one hundred mil...
.After F2G's initial try to receive a brand-new lesson of antifungal to market was hindered by the F...
.Moderna has actually sworn to reduce R&D costs by $1.1 billion by 2027. The decision to retract ...
.Simply four months after Sanofi wager $80 million in ahead of time money on Fulcrum Rehabs' losmapi...
.Cancer company Oncternal Rehabs is actually folding all its own professional trials and giving up w...